DK2062573T3 - Misbrugsresistent opioid indeholdende transdermale systemer - Google Patents

Misbrugsresistent opioid indeholdende transdermale systemer

Info

Publication number
DK2062573T3
DK2062573T3 DK08020810.1T DK08020810T DK2062573T3 DK 2062573 T3 DK2062573 T3 DK 2062573T3 DK 08020810 T DK08020810 T DK 08020810T DK 2062573 T3 DK2062573 T3 DK 2062573T3
Authority
DK
Denmark
Prior art keywords
abuse
transdermal systems
containing transdermal
dosage form
opioid containing
Prior art date
Application number
DK08020810.1T
Other languages
English (en)
Inventor
Lino Tavares
Bruce E Reidenberg
Richard S Sackler
Curtis Wright
Benjamin Oshlack
James P Cassidy
Anthony E Carpanzano
Rampurna Prasad Gullapalli
Ihor Shevchuk
Mark A Alfonso
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK2062573T3 publication Critical patent/DK2062573T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08020810.1T 2001-05-01 2002-04-30 Misbrugsresistent opioid indeholdende transdermale systemer DK2062573T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28787501P 2001-05-01 2001-05-01
US29253701P 2001-05-22 2001-05-22
EP02731653A EP1397095B1 (en) 2001-05-01 2002-04-30 Abuse resistant opioid containing transdermal systems

Publications (1)

Publication Number Publication Date
DK2062573T3 true DK2062573T3 (da) 2012-01-30

Family

ID=26964697

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02731653T DK1397095T3 (da) 2001-05-01 2002-04-30 Misbrugsresistente, opioid-holdige transdermale systemer
DK08020810.1T DK2062573T3 (da) 2001-05-01 2002-04-30 Misbrugsresistent opioid indeholdende transdermale systemer
DK10009943.1T DK2316439T3 (da) 2001-05-01 2002-04-30 Misbrugssikrede transdermale systemer, der indeholder opioider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02731653T DK1397095T3 (da) 2001-05-01 2002-04-30 Misbrugsresistente, opioid-holdige transdermale systemer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10009943.1T DK2316439T3 (da) 2001-05-01 2002-04-30 Misbrugssikrede transdermale systemer, der indeholder opioider

Country Status (11)

Country Link
US (2) US20040241218A1 (da)
EP (3) EP1397095B1 (da)
JP (3) JP5296284B2 (da)
AT (2) ATE533478T1 (da)
CY (2) CY1108821T1 (da)
DE (1) DE60230138D1 (da)
DK (3) DK1397095T3 (da)
ES (3) ES2318010T3 (da)
PT (3) PT2316439E (da)
SI (3) SI2062573T1 (da)
WO (1) WO2002087482A1 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7125561B2 (en) * 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TW200404581A (en) * 2002-04-23 2004-04-01 Alza Corp Transdermal analgesic systems with reduced abuse potential
EP1513532B1 (en) * 2002-06-10 2007-02-28 Euro-Celtique S.A. Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7182955B2 (en) 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DK1638492T3 (da) * 2003-07-25 2008-05-13 Euro Celtique Sa Præoperativ behandling af postoperativ smerte
CA2543610A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
US8535711B2 (en) 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
HRP20090363T1 (hr) * 2004-02-23 2009-08-31 Euro-Celtique S.A. Transdermalni injektor opioida rezistentan na zlouporabu
JP2008510713A (ja) * 2004-08-20 2008-04-10 スリーエム イノベイティブ プロパティズ カンパニー 半透明保護フィルムを有する経皮薬物送達デバイス
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8246977B2 (en) * 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
WO2006069008A1 (en) * 2004-12-22 2006-06-29 Vesta Medical, Llc Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof
US20060182819A1 (en) 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
WO2006124585A2 (en) 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
US20060257460A1 (en) * 2005-05-13 2006-11-16 Jansen Rolf R Multilayer drug delivery system with barrier against antagonist exposure
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
EP2308480B1 (en) 2005-09-23 2014-08-13 ALZA Corporation High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications
US9056061B2 (en) 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
BRPI0619806A2 (pt) * 2005-12-13 2011-10-18 Biodelivery Sciences Int Inc dispositivo para fornecimento de fármacos transmucosal resistente ao abuso
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080008747A1 (en) * 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
US20080286348A1 (en) * 2007-05-16 2008-11-20 Todhunter John A Secured transdermal delivery system
DE102007041557B4 (de) * 2007-08-29 2011-03-31 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend längliche Hohlkörper
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
EP2254561A2 (en) * 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
DE102008016804B4 (de) * 2008-04-02 2012-01-05 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
EP2552425B1 (en) * 2010-04-02 2016-07-27 Buzzz Pharmaceuticals Limited Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
MX352959B (es) 2011-08-18 2017-12-15 Biodelivery Sciences Int Inc Dispositivos mucoadhesivos resistentes al abuso para el suministro de buprenorfina.
WO2013049387A1 (en) 2011-09-30 2013-04-04 Teikoku Pharma Usa, Inc. General medication disposal system
RU2014110700A (ru) 2011-09-30 2015-11-10 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система утилизации трансдермальных пластырей
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
CA2962080A1 (en) 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US20190067725A1 (en) * 2016-02-26 2019-02-28 Case Western Reserve University Composite membranes for flow batteries
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
EP3801732A4 (en) 2018-05-29 2022-04-27 Morningside Venture Investments Limited METHODS AND SYSTEMS FOR DRUG DELIVERY
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
US20210346662A1 (en) * 2018-10-23 2021-11-11 Kindeva Drug Delivery L.P. Tamper evident transdermal patch
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
EP4013390A1 (en) * 2019-08-12 2022-06-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pharmaceutical compositions comprising a combination of opioid antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
WO1997004835A1 (de) 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6554851B1 (en) * 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
EP2266719B1 (en) * 2001-04-23 2016-06-08 Euro-Celtique S.A. Disposal system for transdermal dosage form

Also Published As

Publication number Publication date
PT2316439E (pt) 2015-08-28
EP1397095A1 (en) 2004-03-17
EP1397095B1 (en) 2008-12-03
EP2062573A1 (en) 2009-05-27
JP2004529155A (ja) 2004-09-24
SI2316439T1 (sl) 2015-10-30
PT2062573E (pt) 2012-01-11
JP5296284B2 (ja) 2013-09-25
CY1108821T1 (el) 2014-04-09
ES2377672T3 (es) 2012-03-29
DE60230138D1 (de) 2009-01-15
EP1397095A4 (en) 2005-05-25
EP2062573B1 (en) 2011-11-16
ES2318010T3 (es) 2009-05-01
SI1397095T1 (sl) 2009-04-30
CY1112271T1 (el) 2015-12-09
JP2013144702A (ja) 2013-07-25
ATE415952T1 (de) 2008-12-15
JP2015042649A (ja) 2015-03-05
ATE533478T1 (de) 2011-12-15
US20140199383A1 (en) 2014-07-17
ES2546828T3 (es) 2015-09-29
WO2002087482A1 (en) 2002-11-07
US20040241218A1 (en) 2004-12-02
SI2062573T1 (sl) 2012-02-29
EP2316439B1 (en) 2015-06-17
PT1397095E (pt) 2009-02-17
DK2316439T3 (da) 2015-08-10
EP2316439A1 (en) 2011-05-04
DK1397095T3 (da) 2009-03-09

Similar Documents

Publication Publication Date Title
DK2062573T3 (da) Misbrugsresistent opioid indeholdende transdermale systemer
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
IL170454A (en) Preparations of active ingredients for administration through the skin or through mucous membranes and their uses
EP1506181A4 (en) POLYETHYLENE GLYCOL-HOLDING TAXANE-CONTAINING CYTOTOXIC AGENTS AND THEIR THERAPEUTIC USE
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
DE60212006D1 (de) Vaskuläres Schutzsystem und Angioplastievorrichtung
BR0313627A (pt) Formulações farmacêuticas, processos para a preparação de formulação farmacêutica e método para o tratamento de dores
AU2002227913A1 (en) Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
DE60318237D1 (de) Pharmazeutische zusammensetzungen enthaltend flavonoide und menthol
DE50211758D1 (de) Kosmetische zubereitungen enthaltend polyhexamethhylenbiguanid-hydrochlorid und distearyldimethylammoniumchlorid
DE60135287D1 (de) Saugfähiger Einwegartikel und Schutzmittel
ATE423551T1 (de) Eine missbrauch verhinderende, transdermale dosierungsform, die einen wirkstoff und einen antagonisten des wirkstoffs enthält
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
BR0312782A (pt) Composição para o tratamento de manchas
PL369725A1 (en) Pharmaceutical formulations containing low concentration of peroxide for treating or preventing vaginal infections
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
PT1200071E (pt) Comprimidos fracamente doseados e processo de preparacao
DE60110087D1 (de) Verwendung von Carboanhydrase-Inhibitoren zur Prävention von diabetischer Retinopathie bei Diabetikern
EP1603595A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE
DE60034770D1 (de) Stabile fumagillin-formulierung
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
CY1109316T1 (el) Συνδυαστικη αγωγη για πολλαπλη σκληρυνση
PT1206267E (pt) Medicamentos contendo oligo-ou/e polirribonucleotidos xenogenicos